HALP评分在睾丸癌患者中的预后价值：一项回顾性研究。
Prognostic value of the HALP score in patients with testicular cancer: a retrospective study.
作者信息
Agaoglu Ahmet Burak, Erdogan Atike Pınar, Sahbazlar Mustafa, Ekinci Ferhat
机构信息
Division of Medical Oncology, Faculty of Medicine, Celal Bayar University, Yunusemre, Manisa, Turkey.
出版信息
Clin Transl Oncol. 2025 Jun 17. doi: 10.1007/s12094-025-03973-3.
PURPOSE
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel immune nutritional index associated with the prognosis of various malignancies. This study aimed to evaluate the clinical relevance of the HALP score in predicting recurrence, metastasis, and survival outcomes in patients with testicular cancer.
METHODS
This retrospective study included 131 patients with histologically confirmed testicular cancer who were treated between January 2010 and December 2024. HALP scores were calculated using the baseline laboratory parameters. An optimal cutoff value of 304.56 was identified using receiver operating characteristic (ROC) curve analysis (AUC: 0.820; 95% CI 0.708-0.902; p < 0.001). Patients were stratified into high and low HALP groups based on this threshold value. Survival outcomes were evaluated using Kaplan-Meier, and Cox proportional hazards regression analyses.
RESULTS
The median HALP score was 531.1 (IQR: 348.8-728.5). A low HALP score (≤ 304.56) was significantly associated with poorer 1-year overall survival (54.5% vs. 98.2%, p < 0.001) and a 15.6-fold increased risk of death (HR 15.604, 95% CI 2.718-89.645, p = 0.001) based on Cox regression analysis. In the multivariate analysis, a low HALP score (HR: 7.684, p = 0.016), the presence of comorbidity (HR 13.528, p = 0.002), and tunica albuginea invasion (HR 7.255, p = 0.030) were identified as independent predictors of recurrence or metastasis. In addition, the HALP score was significantly associated with disease stage (p < 0.001), with lower scores more commonly observed in patients with advanced-stage disease.
CONCLUSIONS
The HALP score was a simple, inexpensive, and effective prognostic biomarker in testicular cancer. A score ≤ 304.56 is independently associated with a higher risk of recurrence, metastasis, and mortality. Incorporating HALP into routine assessments may improve risk stratification and clinical decision-making in this patient population.
目的
血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分是一种与多种恶性肿瘤预后相关的新型免疫营养指标。本研究旨在评估HALP评分在预测睾丸癌患者复发、转移和生存结局方面的临床相关性。
方法
这项回顾性研究纳入了131例经组织学确诊的睾丸癌患者，他们在2010年1月至2024年12月期间接受了治疗。使用基线实验室参数计算HALP评分。通过受试者工作特征（ROC）曲线分析确定最佳截断值为304.56（AUC：0.820；95%CI 0.708 - 0.902；p < 0.001）。根据该阈值将患者分为HALP高分组和低分组。使用Kaplan-Meier法和Cox比例风险回归分析评估生存结局。
结果
HALP评分中位数为531.1（IQR：348.8 - 728.5）。基于Cox回归分析，低HALP评分（≤ 304.56）与较差的1年总生存率显著相关（54.5%对98.2%，p < 0.001），死亡风险增加15.6倍（HR 15.604，95%CI 2.718 - 89.645，p = 0.001）。在多变量分析中，低HALP评分（HR：7.684，p = 0.016）、合并症的存在（HR 13.528，p = 0.002）和白膜侵犯（HR 7.255，p = 0.030）被确定为复发或转移的独立预测因素。此外，HALP评分与疾病分期显著相关（p < 0.001），晚期疾病患者中较低评分更为常见。
结论
HALP评分是睾丸癌中一种简单、廉价且有效的预后生物标志物。评分≤304.56与复发、转移和死亡的较高风险独立相关。将HALP纳入常规评估可能会改善该患者群体的风险分层和临床决策。
Zotero 插件